PLB-015 / Primelink Bio - LARVOL DELTA

PLB-015 a novel anti-HER2 dual payload ADC for the treatment of HER2 positive solid tumors (AACR 2026) - "The result of the toxicity study of PLB-015 in cynomolgus monkeys indicates PLB-015 is well tolerated. These preclinical results support PLB-015 as a potential candidate for the treatment of HER2-positive tumors."

ADC • Late-breaking abstract • Oncology • Solid Tumor